BioNTech cuts 2023 revenue guidance by 20%, but touts its financial position
Fierce Pharma
NOVEMBER 6, 2023
Following suit with other companies that produce COVID-19 vaccines, BioNTech has discovered demand for its Pfizer-partnered, omicron-adapted shot has not met expectations this fall and has had to a | BioNTech has slashed its estimate of 2023 revenue by 20%, now expecting it to reach 4 billion euros ($4.3
214 
Let's personalize your content